Biotech Startups

Perceptic builds an AI platform that unifies evidence, data, and decision workflows across the drug development lifecycle, connecting asset scouting, scientific evaluation, and clinical data on a shared intelligence layer. It targets pharmaceutical and drug development organizations, providing traceable, data-backed decision-making with AI-assisted reasoning.

1 investor

Perception Biosystems develops automated manufacturing systems for gene therapy production, aiming to reduce the time and cost of producing therapies for rare disease clinical trials.

1 investor

Perception Medicine develops AI-driven precision oncology solutions for cancer patients. The company's team combines expertise in artificial intelligence, clinical medicine, and product design, with roots in Stanford and MIT research.

1 investor

Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression. The company licenses intellectual property originally discovered at Chiba University and is running a Phase 2a proof-of-concept clinical trial.

1 investor

Performance BioFilaments developed and produced nanofibrillated cellulose (NFC) materials. The company has ceased operations as of February 1, 2026.

1 investor

Performance Plants Inc. (PPI) is an agricultural biotechnology developer that conducts gene discovery and trait development to improve crop yield, drought tolerance, and heat tolerance without introducing foreign genes. Its technologies target staple food crops and biofuel crops to help farmers adapt to climate change, developed at its R&D lab in Kingston, Ontario, Canada.

1 investor

Periotherapia develops antibody-based therapeutics targeting pathological periostin in the stromal environment to treat refractory diseases including cancer, diabetic retinopathy, and heart disease. The company, spun out from Osaka University, is conducting clinical trials for HER2-negative triple-negative breast cancer with support from Japan's AMED program.

1 investor

Perlara is a biopharmaceutical company that develops treatments for ultra-rare genetic diseases using yeast-based disease modeling and drug repurposing strategies. The company operates as a full-stack drug development platform serving rare disease patients and families.

1 investor

GigaCrop develops agricultural biotechnology to improve photosynthesis in crop plants through enzyme engineering, enabling more sustainable and efficient food and materials production. The company focuses initially on major crops like corn and soybean, with plans to expand to plants for biomanufacturing.

1 investor

Permeasis Therapeutics is developing a Membrane Translocation Domain (MTD) platform that enables intracellular delivery of proteins and other large therapeutic macromolecules to the cytosol and intracellular compartments. The company initially targets genetically defined diseases where delivering functional proteins inside cells could have therapeutic impact.

1 investor

1 investor

Perseo Pharma is a biotech spin-off from the University of Applied Sciences in Basel, Switzerland, developing enzyme immobilization and bioconjugation technologies for therapeutic applications. The company focuses on creating novel platforms for drug delivery and enzyme-based therapies targeting inborn errors of metabolism and other rare diseases.

1 investor

PERSEO Biotechnology develops industrial processes that convert organic waste and byproducts into advanced bioethanol, bioproducts, and bioenergy using its own technology. It offers custom waste valorization projects, including industrial plants and innovation services, based on circular economy and sustainability principles.

1 investor

Persephone develops a synbiotic supplement for infants that combines probiotics (keystone Bifidobacterium strains) with prebiotics found in human breast milk to replenish gut bacteria linked to digestion, immunity, and development. The product was developed by microbiome scientists and pediatricians and validated in a clinical study.

1 investor

Perseus SENOLYTIX is a gerotherapeutics company developing senolytic peptides to target senescent cells and restore cellular balance in aging organisms. The company focuses on translating scientific discoveries into therapeutics addressing fundamental mechanisms of aging.

1 investor

Parsian Tarava manufactures needle-style reusable electrodes for electroporation applications in gene transfer and drug delivery across in vivo, ex vivo, and in ovo conditions. The electrodes are designed for use in research, biomedical, genetic, and pharmaceutical settings.

1 investor

1 investor

Perspectum develops digital medical technology and diagnostics using multiparametric MRI to assess and diagnose chronic systemic diseases including liver disease, long COVID, diabetes, and cancer for clinicians and patients.

1 investor

Persuasive develops a platform technology for high-throughput analysis of extracellular vesicles (EVs) and is building a blood-based diagnostic test using an EV protein biomarker signature to identify chronic coronary syndrome in primary-care patients presenting with chest pain. The company, spun out with UMC Utrecht researchers, targets early diagnosis of stable angina to reduce unnecessary hospital referrals.

1 investor

Petrichor Capital Partners is a venture capital and private equity firm that invests in life sciences and biotech companies, with operations including a dedicated operating partner network and advisory board of scientific and medical experts.

1 investor

PexMachina develops physics-based molecular simulation for drug discovery, using quantum-ready computational chemistry and AI agents to predict properties like binding, stability, and oral availability of peptides. It delivers its PexAgent as an MCP service that integrates into LLM platforms such as Claude and Gemini, letting pharmaceutical researchers run molecular simulations via natural language within existing R&D workflows.

1 investor

Pexxes develops affordable biologic therapeutics for treating chronic diseases in dogs, cats, and horses. The company uses advanced antibody discovery technologies including phage display to create high-affinity binders for veterinary medicine applications.

1 investor

Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.

1 investor

Pfenex provides a Pseudomonas fluorescens-based microbial expression platform for manufacturing recombinant proteins, antibodies, and biologics at scale. The platform supports development from construct to production strain and enables technology transfer to CDMOs and manufacturing partners.

1 investor